<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-23.anc" start="19770" end="19777" sStart="-1" offset="0" sid="null" wn="1" wnkey="write%2:36:00::" text="JRD extracted data, contributed to the protocol &lt;b&gt;writing&lt;/b&gt;, extracted and analyzed data, contributed to the drafts and approved the final version of the paper." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-23.anc" start="13813" end="13817" sStart="null" offset="52" sid="r7.1.use.v.0187" wn="1" wnkey="use%2:34:01::" text="A previous SR [ 5 6 ] pooled 12 trials that used subcutaneous EPO (all also included in our analysis) in a Bayesian MA reached results similar [OR = 0.38; 95%CI: 0.28 to 0.51] to ours." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-23.anc" start="5834" end="5841" sStart="null" offset="0" sid="null" wn="1" wnkey="success%1:11:00::" text="The qualitative conclusion of the authors was assessed using the method described by Gilberts and Colditz [ 19 20 ] and adapted to a six point scale, where 1 = control group highly preferred, 2 = control preferred to EPO treatment, 3 = about equal, EPO a disappointment, 4 = about equal, EPO a &lt;b&gt;success&lt;/b&gt;, 5 = EPO preferred to control and 6 = EPO highly preferred." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-23.anc" start="5834" end="5841" sStart="null" offset="0" sid="null" wn="3" wnkey="success%1:26:00::" text="The qualitative conclusion of the authors was assessed using the method described by Gilberts and Colditz [ 19 20 ] and adapted to a six point scale, where 1 = control group highly preferred, 2 = control preferred to EPO treatment, 3 = about equal, EPO a disappointment, 4 = about equal, EPO a &lt;b&gt;success&lt;/b&gt;, 5 = EPO preferred to control and 6 = EPO highly preferred." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-23.anc" start="5834" end="5841" sStart="null" offset="0" sid="null" wn="1" wnkey="success%1:11:00::" text="The qualitative conclusion of the authors was assessed using the method described by Gilberts and Colditz [ 19 20 ] and adapted to a six point scale, where 1 = control group highly preferred, 2 = control preferred to EPO treatment, 3 = about equal, EPO a disappointment, 4 = about equal, EPO a &lt;b&gt;success&lt;/b&gt;, 5 = EPO preferred to control and 6 = EPO highly preferred." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-23.anc" start="8420" end="8426" sStart="null" offset="106" sid="r11.strong.j.0819" wn="1 6" wnkey="null" text="All trials scored five or six on the six point Gilbert [ 19 ] and Colditz [ 20 ] scales, denoting strong qualitative support in favor of EPO ((see Additional file 1))." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-23.anc" start="2499" end="2505" sStart="null" offset="14" sid="r7.serve.v.0849" wn="1" wnkey="serve%2:42:03::" text="A previous SR served as a basis for location of the articles of interest [ 5 ] . We also performed a search of MEDLINE, LILACS and CANCERLIT databases, last update in July of 2001, using the optimal search strategy for RCT for use in MEDLINE [ 10 ] and LILACS [ 11 ] with the additional terms related to this review - (epoetin OR Erythropoietin) and (cancer OR neoplasm), in all fields." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-23.anc" start="13445" end="13449" sStart="null" offset="122" sid="r7.poor.j.0677" wn="5" wnkey="poor%5:00:00:insufficient:00" text="We also tried to extract data on adverse events, but were unable to make a reasonable approach due to the poor reporting." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-23.anc" start="13445" end="13449" sStart="null" offset="122" sid="r7.poor.j.0677" wn="4" wnkey="poor%3:00:02::" text="We also tried to extract data on adverse events, but were unable to make a reasonable approach due to the poor reporting." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-23.anc" start="19888" end="19893" sStart="null" offset="174" sid="r9.paper.n.0860" wn="5" wnkey="paper%1:10:02::" text="JRD extracted data, contributed to the protocol writing, extracted and analyzed data, contributed to the drafts and approved the final version of the paper." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-23.anc" start="15467" end="15471" sStart="null" offset="66" sid="r8.life.n.0503" wn="2" wnkey="life%1:09:00::" text="Because it was not possible to extract data on quality of life (QOL), this issue was not addressed here." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-23.anc" start="10774" end="10779" sStart="null" offset="55" sid="r9.level.n.0505" wn="1" wnkey="level%1:07:00::" text="When we divided the trials according to the hb level, using 11." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-23.anc" start="6198" end="6203" sStart="null" offset="290" sid="r9.level.n.0236" wn="2" wnkey="level%1:26:01::" text="Finally, we performed a cumulative meta-analysis (CMA) [ 8 ] using a conservative approach, setting the ? error at 1%, with a two tailored &quot;p&quot; in a random effects model [ 21 ] . The CMA allowed us to determine the point when the results achieved a level of statistical significance after which we should expect no changes in the effect by performing new trials, and after which placebo controlled trials should not have been performed." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-23.anc" start="7696" end="7701" sStart="null" offset="63" sid="r9.level.n.0518" wn="1" wnkey="level%1:07:00::" text="5 g/dl and five trials with 369 patients related to hb level &gt;= 11." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-23.anc" start="9424" end="9428" sStart="null" offset="114" sid="r10.high.j.0528" wn="1" wnkey="high%3:00:02::" text="This is likely because in this small study including 10 patients in each group, event rate was so high with all but one patient receiving transfusion." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-23.anc" start="15132" end="15136" sStart="null" offset="119" sid="r10.high.j.0498" wn="1" wnkey="high%3:00:02::" text="Nevertheless, we should mention (see the RESULTS) that the most of heterogeneity could be explained by high transfusion rates in the trial by Porter et al." />
    <s path="file:/C:/OANC/data/written_2/technical/biomed/1471-2407-2-23.anc" start="5325" end="5333" sStart="null" offset="0" sid="null" wn="1" wnkey="exercise%2:34:00::" text="However, the readers are advised to &lt;b&gt;exercise&lt;/b&gt; due caution because NNT and NNH (number of patients to harm) are more influenced by the baseline risk in a control group than the odds ratio." />
    <s path="file:/C:/OANC/data/written_2/technical/biomed/1471-2407-2-23.anc" start="5325" end="5333" sStart="null" offset="0" sid="null" wn="2" wnkey="exercise%2:41:00::" text="However, the readers are advised to &lt;b&gt;exercise&lt;/b&gt; due caution because NNT and NNH (number of patients to harm) are more influenced by the baseline risk in a control group than the odds ratio." />
    <s path="file:/C:/OANC/data/written_2/technical/biomed/1471-2407-2-23.anc" start="5325" end="5333" sStart="null" offset="0" sid="null" wn="1" wnkey="exercise%2:34:00::" text="However, the readers are advised to &lt;b&gt;exercise&lt;/b&gt; due caution because NNT and NNH (number of patients to harm) are more influenced by the baseline risk in a control group than the odds ratio." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-23.anc" start="1408" end="1417" sStart="null" offset="182" sid="r8.1.different.j.0022" wn="2" wnkey="different%5:00:00:other:00" text="Although comprehensive, some issues were not addressed in this previous SR/MA: a formal quantitative synthesis (meta-analysis) was not performed according to different clinical aspects and to main methodological quality dimensions empirically linked to bias [ 7 ] ." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-23.anc" start="1408" end="1417" sStart="null" offset="182" sid="r8.1.different.j.0022" wn="1" wnkey="different%3:00:00::" text="Although comprehensive, some issues were not addressed in this previous SR/MA: a formal quantitative synthesis (meta-analysis) was not performed according to different clinical aspects and to main methodological quality dimensions empirically linked to bias [ 7 ] ." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-23.anc" start="1408" end="1417" sStart="null" offset="182" sid="r8.1.different.j.0022" wn="1" wnkey="different%3:00:00::" text="Although comprehensive, some issues were not addressed in this previous SR/MA: a formal quantitative synthesis (meta-analysis) was not performed according to different clinical aspects and to main methodological quality dimensions empirically linked to bias [ 7 ] ." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-23.anc" start="14110" end="14119" sStart="null" offset="140" sid="r8.1.different.j.0915" wn="1" wnkey="different%3:00:00::" text="We could also demonstrate consistency of the results when analyzed according to OR, RR, various quality dimensions and many different clinical settings (fig 2and 3)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-23.anc" start="1408" end="1417" sStart="null" offset="182" sid="r8.1.different.j.0022" wn="1" wnkey="different%3:00:00::" text="Although comprehensive, some issues were not addressed in this previous SR/MA: a formal quantitative synthesis (meta-analysis) was not performed according to different clinical aspects and to main methodological quality dimensions empirically linked to bias [ 7 ] ." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-23.anc" start="3798" end="3805" sStart="null" offset="130" sid="r10.control.n.0119" wn="4" wnkey="control%1:09:02::" text="In the second we combined all active arms in one, by adding all EPO treated patients, and analyzed it against the control." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-23.anc" start="3812" end="3824" sStart="null" offset="5" sid="r11.combination.n.0149" wn="1" wnkey="combination%1:14:00::" text="Both combinations achieved virtually the same result and data are presented using the second method." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-23.anc" start="12697" end="12704" sStart="null" offset="188" sid="r11.benefit.n.0694" wn="2" wnkey="benefit%1:07:00::" text="Our CMA demonstrated that by 1995 a high level of significance [OR = 0.52; 99%CI: 0.28 to 0.97; p = 0.0068]; [RR = 0.69; 99%CI: 0.53 to 0.90; p = 0.0003] about the benefit of EPO on reducing the use of blood transfusions had been achieved." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-23.anc" start="14251" end="14259" sStart="null" offset="83" sid="r11.benefit.n.0989" wn="2" wnkey="benefit%1:07:00::" text="Due to these EPO effects, patients with cancer are expected to have direct benefits through fewer transfusions and lower exposure to anemia effects." />
  </sentences>
</list>